Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 13, 2021 / 05:15PM GMT
Release Date Price: R$21.08 (-2.14%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

I'm Matthew Harrison, one of the biopharma analysts here at Morgan Stanley. Very pleased to have Sarepta with us for the next session. Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/research disclosures.

And so with that, very pleased to have Doug Ingram, I'm the CEO; and Ian Estepan, the CFO from Sarepta. Doug, I'm going to turn it over to you to make some opening comments, and then we can get into Q&A.

Ian Michael Estepan
Sarepta Therapeutics, Inc. - Executive VP & CFO

Thank you.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you very much, Matthew, and thanks for having us today. I think I made a promise in advance of the call that I will filibuster. So I'll be short. 2021 has been a very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot